Notizie

(RTTNews) - Bristol Myers Squibb (BMY) posted a first quarter net loss attributable to Bristol Myers Squibb of $11.9 billion, or $5.89 per share, compared to net income of $2.3 billion, or $1.07 per share, a year ago. On a non-GAAP basis, net loss attributable to Bristol Myers Squibb was $8.9 billion, or $4.40 per share, compared to net profit of $4.3 billion, or $2.05 per share, last year. On average, 17 analysts polled by Thomson Reuters expected the company to report a loss per share of $4.44, for the quarter. Analysts' estimates typically exclude special items.

Net product sales were $11.56 billion compared to $11.05 billion, last year. Revenues were $11.9 billion, an increase of 5% or 6% when adjusted for foreign exchange impacts, primarily driven by Eliquis, Reblozyl and Opdualag, partially offset by Opdivo and Revlimid. Analysts on average had estimated $11.46 billion in revenue. U.S. revenues increased 7% to $8.5 billion.

Bristol Myers Squibb updated portions of its 2024 line-item guidance, including non-GAAP EPS, to reflect the impact of recent transactions. Total deals impact was $6.73. As a result, revised non-GAAP EPS guidance is $0.40 - $0.70. Analysts expect the company to report profit per share of $0.65.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.